Related Experiment Videos
Prostaglandin E1 prevents increased lung microvascular permeability during intravascular complement activation in
Circulation Research
|September 1, 1987
Summary
Prostaglandin E1 (PGE1) effectively prevents lung microvascular injury caused by complement activation. This study shows PGE1 inhibits neutrophil adherence, reducing lung lymph flow and vascular permeability in sheep.
Area of Science:
- Pulmonary Medicine
- Immunology
- Pharmacology
Background:
- Activated neutrophils contribute to lung vascular injury.
- Prostaglandin E1 (PGE1) is known to inhibit neutrophil functions.
- The effect of PGE1 on complement-induced lung injury requires investigation.
Purpose of the Study:
- To determine if Prostaglandin E1 (PGE1) alters the pathophysiology of complement-induced lung vascular injury.
- To investigate the protective mechanisms of PGE1 in this injury model.
Main Methods:
- Anesthetized sheep with lung lymph fistulas were used.
- Zymosan-activated plasma was infused to induce lung injury.
- Prostaglandin E1 (PGE1) or saline vehicle was administered intravenously prior to injury induction.
Main Results:
- PGE1 did not affect leukocyte count, hypoxemia, thromboxane A2 release, or acute pulmonary hypertension.
- PGE1 prevented the increase in lung lymph flow, indicating reduced microvascular permeability.
- Pulmonary endothelial cell extraction of PGE1 was not affected by activated plasma infusion.
Conclusions:
- Prostaglandin E1 (PGE1) effectively mitigates complement-induced increases in lung microvascular permeability.
- PGE1 likely exerts its protective effect by inhibiting the adherence of activated neutrophils to endothelial cells.
- PGE1 represents a potential therapeutic agent for managing lung vascular injury.